Antidepressant Labeling Should Reflect Negative Pediatric Studies
Executive Summary
Antidepressant labeling should be revised to reflect negative efficacy data for pediatric patients, a joint FDA advisory committee suggested Feb. 2
You may also be interested in...
HMO Claims Study Will Provide Next Data For Antidepressant Safety Review
A 24,000-patient pediatric safety study currently under peer review could provide the next pool of data on the relationship between antidepressants and suicidality
HMO Claims Study Will Provide Next Data For Antidepressant Safety Review
A 24,000-patient pediatric safety study currently under peer review could provide the next pool of data on the relationship between antidepressants and suicidality
Antidepressant Suicidality Needs Interim Risk Management, FDAer Maintains
FDA should establish an interim risk management plan to discourage pediatric antidepressant use, FDA epidemiologist Andrew Mosholder, MD, maintained in an Aug. 16 memo